Status:
COMPLETED
Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Migraine
Eligibility:
All Genders
18-100 years
Brief Summary
This was a retrospective registry-based study utilizing data collected in association with clinical care of patients. All data was stored in electronic health records at Terveystalo data base, and no ...
Detailed Description
Patients initiating erenumab treatment between 20.9.2018 - 15.10. 2019, and data on sick leave days, diagnoses and health care visits as well as medications based on prescriptions were assessed. Foll...
Eligibility Criteria
Inclusion
- Adult patients on erenumab treatment ATC: N02CX07
- Diagnosis of migraine (ICD G43)
- Consented
- Occupational healthcare
Exclusion
- None
Key Trial Info
Start Date :
July 3 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 14 2021
Estimated Enrollment :
162 Patients enrolled
Trial Details
Trial ID
NCT05375097
Start Date
July 3 2020
End Date
May 14 2021
Last Update
July 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
East Hanover, New Jersey, United States, 07936-1080